ImmuPharma PLC (AIM:IMM, OTC:IMMPF)'s (ImmuPharma PLC (AIM:IMM, OTC:IMMPF), ImmuPharma PLC (AIM:IMM, OTC:IMMPF)) chief executive, Tim McCarthy talks to Proactive London's Katie Pilbeam about plans for their Lupuzor treatment to assess how a new formulation of the lupus treatment interacts with the body.
After approval from the UK’s Medical and Health Products Regulatory Agency, the pharmacokinetic (PK) study in 24 healthy male volunteers will get underway on February 15.
Results should be available by the end of the current quarter.